Business
Clene is a clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics, led by CNM-Au8 for neurodegenerative disease programs.
Clene losses narrowed, but equity stayed negative and insider sales dominated.
The read at a glance✓ Audited against SEC data
- Business mix — CNM-Au8 nanotherapyNote
- Revenue — $0.2M, -41.5%Watch
- Net loss — $26.2M, narrowerOK
- FCF — ($18.6M), improvedOK
- Equity — negative $17.6MWatch
- Altman/Beneish/EQ — Weak Z; EQ greyWatch
- Insiders — 1 purchase / 61 salesWatch
Where the revenue comes from
Fiscal 2025, as Clene Inc. reports it. History and quarterly detail are in the app.
- Product$119K
- Royalty$81K
Leadership changes
From Clene Inc.'s own filings, the day they're filed.
- Professor Matthew Kiernan · Directors · appointmenteff. 2023-09-18
- Jonathon T. Gay · director · appointmenteff. 2023-09-18
- Brain Foundation · appointment
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-05-22
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Clene Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.